Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?
HPB · 2026-07 · 28 (7) · 918-925
DOI: 10.1016/j.hpb.2026.04.448 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2026-07. Verfasst von Xiang Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Rutgers Cancer Institute, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Vulnerable Populations, Clinical Trials as Topic. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Hepatocellular carcinoma (HCC) is more common in vulnerable populations, but the impact of social vulnerability on clinical trial participation remains unclear. METHODS Adults with a diagnosis of HCC between 2019 and 2023 in the United States-based Vizient Clinical Database were analyzed. Univariate and multivariable analyses evaluated the association between the Vizient Vulnerability Index (VVI), a census track level measure of social vulnerability, and clinical trial participation. Interaction tests were performed for race/ethnicity and VVI. RESULTS Among 201,704 HCC patients, 2.1% participated in a clinical trial. Participants were more often White (57% vs 53%), commercially insured (27% vs 22%), had MELD-Na
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Rutgers Cancer Institute, New Brunswick, NJ, USA.
- Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
- Rutgers Cancer Institute, New Brunswick, NJ, USA.
- Vizient Clinical Database Inc, Irving, TX, USA.
- Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Rutgers Cancer Institute, New Brunswick, NJ, USA. Electronic address: Henry.Pitt@rwjbh.org.
Zitieren
APA
Gao, X., Perati, S. R., Mohayya, S. M., Shippey, E., Pitt, H. A., & Eskander, M. F. (2026). Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?. HPB, 28(7), 918-925. https://doi.org/10.1016/j.hpb.2026.04.448
Vancouver
Gao X, Perati SR, Mohayya SM, Shippey E, Pitt HA, Eskander MF. Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?. HPB. 2026;28(7):918-925. doi:10.1016/j.hpb.2026.04.448
BibTeX
@article{Gao2026,
author = {Gao, Xiang and Perati, Shruthi R and Mohayya, Sana M and Shippey, Ernie and Pitt, Henry A and Eskander, Mariam F},
title = {Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?},
journal = {HPB},
year = {2026},
volume = {28},
number = {7},
pages = {918--925},
doi = {10.1016/j.hpb.2026.04.448}
}
EUVIMED